MS Emerging Therapies Collaborative Highlights New FDA Drug Warnings

February 21, 2012

Share:

The Multiple Sclerosis Emerging Therapies Collaborative has created a new area on its website to post updated information on new treatments, including breaking drug safety communications recently issued by the Food and Drug Administration (FDA) for the drugs natalizumab (Tysabri) and fingolimod (Gilenya). Read the updates.

For more information on these communications and to access other information sheets on MS treatments, which include known benefits and risks as well as answers to commonly asked questions, visit www.ms-coalition.org/EmergingTherapies.

Read the information sheets now.

The content is tailored to suit both clinicians and the public to facilitate effective communication and medical decision making. The AAN and MS Coalition members all have a stake in ensuring their constituencies receive the most accurate drug information, given there are a large number of competing information sources.

For more information, contact emergingtherapies@ms-coalition.org.